- Home
- GLDD vs ABUS Comparison
GLDD vs ABUS Comparison
Compare GLDD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDD
- ABUS
- Stock Information
- Founded
- GLDD 1890
- ABUS 2005
- Country
- GLDD United States
- ABUS United States
- Employees
- GLDD N/A
- ABUS N/A
- Industry
- GLDD Military/Government/Technical
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- GLDD Industrials
- ABUS Health Care
- Exchange
- GLDD Nasdaq
- ABUS Nasdaq
- Market Cap
- GLDD 671.1M
- ABUS 672.1M
- IPO Year
- GLDD 2006
- ABUS N/A
- Fundamental
- Price
- GLDD $11.18
- ABUS $3.36
- Analyst Decision
- GLDD Buy
- ABUS Strong Buy
- Analyst Count
- GLDD 1
- ABUS 4
- Target Price
- GLDD $14.00
- ABUS $5.50
- AVG Volume (30 Days)
- GLDD 679.9K
- ABUS 843.8K
- Earning Date
- GLDD 05-06-2025
- ABUS 05-14-2025
- Dividend Yield
- GLDD N/A
- ABUS N/A
- EPS Growth
- GLDD 79.53
- ABUS N/A
- EPS
- GLDD 1.02
- ABUS N/A
- Revenue
- GLDD $806,898,000.00
- ABUS $6,403,000.00
- Revenue This Year
- GLDD $9.13
- ABUS $14.57
- Revenue Next Year
- GLDD $4.58
- ABUS $15.84
- P/E Ratio
- GLDD $10.94
- ABUS N/A
- Revenue Growth
- GLDD 28.03
- ABUS N/A
- 52 Week Low
- GLDD $7.51
- ABUS $2.71
- 52 Week High
- GLDD $12.89
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- GLDD 63.31
- ABUS 53.55
- Support Level
- GLDD $10.50
- ABUS $3.04
- Resistance Level
- GLDD $11.33
- ABUS $3.54
- Average True Range (ATR)
- GLDD 0.29
- ABUS 0.14
- MACD
- GLDD -0.03
- ABUS 0.02
- Stochastic Oscillator
- GLDD 64.76
- ABUS 70.00
About GLDD Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.